Inhibición de PCSK9: una nueva alternativa para reducir el colesterol y prevenir la enfermedad cardiovascular aterosclerosa

Gabriela Alexandra Solano Peña; Gabriela Fernanda Acurio Armas; Gabriela Alejandra Díaz Teran; Susana Patricia Palacios Serrano; Andrea Carolina Cobo Reyes; Daniel Albino Pullas Taboada; Gissel Katherine Carvajal Chango

doi:10.56294/saludcyt2023587

Review

Published: 2023-11-13

DOI: https://doi.org/10.56294/saludcyt2023587

PCSK9 inhibition: a new alternative to reduce cholesterol and prevent atherosclerotic cardiovascular disease

Abstract

Introduction: Atherosclerotic cardiovascular disease is the leading cause of mortality and morbidity worldwide. One of the key factors in its development is elevated LDL cholesterol. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a molecule that regulates LDL cholesterol levels.
Objective: The purpose of this review is to provide a comprehensive analysis of the evidence surrounding PCSK9 inhibition as an effective therapy for reducing cholesterol and preventing atherosclerotic cardiovascular disease.
Methodology: A comprehensive literature review was conducted using medical databases, including PubMed, Embase, and Cochrane Library. Search terms included "PCSK9," "PCSK9 inhibitors," "cholesterol," "LDL," and "atherosclerotic cardiovascular disease."
Results: Evidence suggests that PCSK9 inhibitors are effective in reducing LDL cholesterol levels in patients with hypercholesterolemia. Several clinical trials have demonstrated that these drugs can reduce LDL cholesterol by up to 60% compared to placebo. Additionally, PCSK9 inhibitors appear to have a favorable safety profile and are well-tolerated by most patients. Several studies have also shown that PCSK9 inhibitors can reduce the risk of cardiovascular events in patients with pre-existing atherosclerotic disease.
Conclusion: PCSK9 inhibitors represent a promising therapeutic strategy for LDL cholesterol control and prevention of atherosclerotic cardiovascular disease. Future studies should focus on determining the long-term effect of these drugs on cardiovascular morbidity and mortality and exploring ways to improve access and affordability to these therapies.

Keywords:

PCSK9,

PCSK9 inhibitors,

LDL cholesterol,

atherosclerotic cardiovascular disease,

antilipid therapy,

How to Cite

Solano Peña GA, Acurio Armas GF, Díaz Teran GA, Palacios Serrano SP, Cobo Reyes AC, Pullas Taboada DA, Carvajal Chango GK. PCSK9 inhibition: a new alternative to reduce cholesterol and prevent atherosclerotic cardiovascular disease. Salud, Ciencia y Tecnología [Internet]. 2023 Nov. 13 [cited 2024 Jul. 27];3:587. Available from: https://revista.saludcyt.ar/ojs/index.php/sct/article/view/587

Copyright Notice

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

Vol. 3 (2023)

See full issue

Revistas/Journals

Issue

About

Author Guidelines